Drug Manufacturing Has One Huge Flaw. This Synthetic Biology Startup Just Raised $200 Million To Fix It. What’s the holy grail of biology? This startup says it’s engineerable cells, and with $200million of new funding for their CAD platform to program genetic circuits, the manufacture of biological therapeutics is set to radically change. Read how: